Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia.
Anemia
HFpEF
Hepcidin
VEGF
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
21
07
2022
accepted:
22
09
2022
pubmed:
8
10
2022
medline:
10
1
2023
entrez:
7
10
2022
Statut:
ppublish
Résumé
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors might improve renal anemia maintaining fewer cardiovascular complications. However, its safety and efficacy, as well as its impact on inflammatory biomarkers, in heart failure patients remain unknown. We initiated HIF-PH inhibitors in 13 patients with chronic heart failure and renal anemia (median age 77 years, median estimated glomerular filtration rate 24.9 mL/min/1.73m
Identifiants
pubmed: 36205772
doi: 10.1007/s00380-022-02181-1
pii: 10.1007/s00380-022-02181-1
doi:
Substances chimiques
Prolyl-Hydroxylase Inhibitors
0
Prolyl Hydroxylases
EC 1.14.11.-
Hypoxia-Inducible Factor-Proline Dioxygenases
EC 1.14.11.29
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
284-290Informations de copyright
© 2022. Springer Japan KK, part of Springer Nature.
Références
Anand IS, Gupta P (2018) Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 138(1):80–98
doi: 10.1161/CIRCULATIONAHA.118.030099
Anand IS (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52(7):501–511
doi: 10.1016/j.jacc.2008.04.044
van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44(1):63–67
doi: 10.1016/j.jacc.2004.03.052
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219
doi: 10.1056/NEJMoa1214865
Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815–826
doi: 10.1053/j.ajkd.2016.12.011
Eleuteri E, Di Stefano A, Giordano A, Corra U, Tarro Genta F, Gnemmi I, Giannuzzi P (2016) Prognostic value of angiopoietin-2 in patients with chronic heart failure. Int J Cardiol 212:364–368
doi: 10.1016/j.ijcard.2016.03.005
Poss J, Ukena C, Kindermann I, Ehrlich P, Fuernau G, Ewen S, Mahfoud F, Kriechbaum S, Bohm M, Link A (2015) Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin Res Cardiol 104(5):380–387
doi: 10.1007/s00392-014-0787-y
Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 62(5):849–859
doi: 10.1053/j.ajkd.2013.06.008
Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117(17):4425–4433
doi: 10.1182/blood-2011-01-258467
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276
doi: 10.1172/JCI200420945
Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS (2012) Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7(12):1938–1946
doi: 10.2215/CJN.03500412
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055–2059
doi: 10.1161/01.CIR.103.16.2055
von Haehling S, Anker SD (2011) Cardio-renal anemia syndrome. Contrib Nephrol 171:266–273
doi: 10.1159/000327342
Kurata Y, Tanaka T, Nangaku M (2020) Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 29(4):414–422
doi: 10.1097/MNH.0000000000000617
Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, Nuti R (2007) Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154(4):645.e9–15
doi: 10.1016/j.ahj.2007.07.022